Kofarest-LS Junior Syrup is a combination pharmaceutical formulation containing Levosalbutamol (0.5 mg/5 ml), Ambroxol (15 mg/5 ml), and Guaifenesin (50 mg/5 ml), designed for pediatric use in the management of respiratory conditions characterized by bronchospasm, excessive mucus production, and productive cough. Levosalbutamol, a selective β2-adrenergic receptor agonist, acts as a bronchodilator by relaxing bronchial smooth muscle, thereby alleviating bronchospasm and improving airflow. Ambroxol serves as a mucolytic agent, facilitating the breakdown and clearance of viscous mucus from the respiratory tract, enhancing mucociliary clearance. Guaifenesin functions as an expectorant, promoting the liquefaction of mucus and aiding in its expectoration, which helps relieve chest congestion. This synergistic combination provides comprehensive symptomatic relief in conditions such as bronchitis, asthma, and other obstructive airway diseases in children. Kofarest-LS Junior Syrup is administered orally, with dosage tailored according to age and clinical severity. It is generally well tolerated; however, caution is advised in patients with hypersensitivity to any component, cardiovascular disorders, or hyperthyroidism. Healthcare professionals should monitor for potential side effects such as tachycardia, tremors, or gastrointestinal disturbances. Overall, Kofarest-LS Junior Syrup offers an effective therapeutic option for pediatric patients requiring bronchodilation, mucolysis, and expectoration support.